PBT2 will totally disrupt the present $8 B human and $ X B ( bigger than $8 B) food production antibiotic-resistant market by helping even the generic antibiotics to kill these previously resistant bacteria and preventing that no new resistant bacteria will be developing when antibiotics are and needed to be used. Think about risk populations who need antibiotics because of their infections. PBT2 needs to be included in the prevention of antibiotic-resistant bacteria. This was demonstrated beautifully in the De Oliviera paper even it was still a laboratory paper.
The many interests in this issue are causing many problems when negotiating the deal or deals. Big Pharma is for sure at the negotiation table and ATH is not represented by Stamler et al, but some hired experts including also expert microbiologists, I would think. In the De Oliviera paper there were 31 bacteriologists and they all know bacteria better than Stamler et al. Many lawyers representing each interest group will be there. $8 B market has a New Deal.
Something big is cooking.
Antibiotic-resistant problem: Urgent, serious and concerns of CDC (USA), page-13
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $4.233K | 885.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 69 | 90514720 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 20531083 | 18 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
0.5¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 0.5¢ | 0.5¢ | 0.5¢ | 500000 | ||
| Last updated 15.07pm 14/06/2024 ? | |||||
| ATH (ASX) Chart |